Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Goserelin acetate (JAN/USP)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 645,518Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 145781-92-6, Fertilan, Zoladex, Goserelin (acetate), Goserelin acetate [jan], 6yuu2pv0u8
    Molecular Formula
    C61H88N18O16
    Molecular Weight
    1329.5  g/mol
    InChI Key
    IKDXDQDKCZPQSZ-JHYYTBFNSA-N
    FDA UNII
    6YUU2PV0U8
    A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
    2.1.2 InChI
    InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1
    2.1.3 InChI Key
    IKDXDQDKCZPQSZ-JHYYTBFNSA-N
    2.1.4 Canonical SMILES
    CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O
    2.1.5 Isomeric SMILES
    CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    6YUU2PV0U8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Acetate, Goserelin

    2. Goserelin

    3. Ici 118630

    4. Ici-118630

    5. Ici118630

    6. Zoladex

    2.3.2 Depositor-Supplied Synonyms

    1. 145781-92-6

    2. Fertilan

    3. Zoladex

    4. Goserelin (acetate)

    5. Goserelin Acetate [jan]

    6. 6yuu2pv0u8

    7. Dsstox_cid_26736

    8. Dsstox_rid_81865

    9. Dsstox_gsid_46736

    10. 1-9-luteinizing Hormone-releasing Factor (swine), 6-(o-(1,1-dimethylethyl)-d-serine)-, 2-(aminocarbonyl)hydrazide, Acetate (salt)

    11. Cas-145781-92-6

    12. Ici-118630 Acetate

    13. Unii-6yuu2pv0u8

    14. Novgos

    15. Zoladex La

    16. Zoladex (tn)

    17. Ncgc00167588-02

    18. Ncgc00183275-01

    19. Schembl6094

    20. Goserelin Acetate (jan/usp)

    21. Chembl1200501

    22. Dtxsid9046736

    23. Goserelin Acetate [vandf]

    24. Goserelin Acetate [mart.]

    25. Glxc-26187

    26. Goserelin Acetate [usp-rs]

    27. Goserelin Acetate [who-dd]

    28. Tox21_112579

    29. Tox21_112937

    30. Bdbm50247974

    31. Hy-13673a

    32. Ici118630

    33. Mfcd01747329

    34. Cs-4509

    35. Goserelin Acetate [orange Book]

    36. (d-ser(tbu)6,azagly10)-lhrh Acetate

    37. Goserelin Acetate [usp Monograph]

    38. D00573

    39. 781g926

    40. Goserelin Acetate, >=99% (hplc), White Powder

    41. Q27265738

    42. Goserelin, European Pharmacopoeia (ep) Reference Standard

    43. H-pyr-his-trp-ser-tyr-d-ser(tbu)-leu-arg-pro-nhnhconh2 Acoh

    44. Goserelin Acetate, United States Pharmacopeia (usp) Reference Standard

    45. Goserelin For Nmr Identification, European Pharmacopoeia (ep) Reference Standard

    46. 6-[o-(1,1-dimethylethyl)-d-serine]-1-9-luteinizing Hormone-releasing Factor (swine) 2-(aminocarbonyl)hydrazide Acetate (salt)

    2.4 Create Date
    2007-05-07
    3 Chemical and Physical Properties
    Molecular Weight 1329.5 g/mol
    Molecular Formula C61H88N18O16
    Hydrogen Bond Donor Count18
    Hydrogen Bond Acceptor Count18
    Rotatable Bond Count32
    Exact Mass1328.66256879 g/mol
    Monoisotopic Mass1328.66256879 g/mol
    Topological Polar Surface Area533 Ų
    Heavy Atom Count95
    Formal Charge0
    Complexity2590
    Isotope Atom Count0
    Defined Atom Stereocenter Count9
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Antineoplastic Agents, Hormonal

    Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

    4.2 FDA Pharmacological Classification
    4.2.1 Pharmacological Classes
    Gonadotropin Releasing Hormone Receptor Agonists [MoA]; Gonadotropin Releasing Hormone Receptor Agonist [EPC]